CMPS
COMPASS Pathways plc NASDAQ Listed Sep 18, 2020$9.76
Pre-mkt
$9.82
+0.61%
Mkt Cap $937.8M
52w Low $2.25
94.3% of range
52w High $10.21
50d MA $6.89
200d MA $6.10
P/E (TTM)
-2.9x
EV/EBITDA
-2.9x
P/B
—
Debt/Equity
-0.4x
ROE
544.7%
P/FCF
-4.1x
RSI (14)
—
ATR (14)
—
Beta
2.02
50d MA
$6.89
200d MA
$6.10
Avg Volume
4.2M
About
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited an…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.41 | -0.59 | -43.9% | 5.22 | +1.7% | +7.7% | +8.0% | +2.9% | +0.4% | +5.9% | — |
| Nov 4, 2025 | AMC | -0.40 | -0.38 | +5.0% | 6.63 | -1.4% | -17.2% | -15.7% | -17.8% | -13.4% | -14.0% | — |
| Jul 31, 2025 | AMC | -0.37 | -0.38 | -2.7% | 4.35 | -1.8% | -0.2% | +5.7% | +3.0% | +0.2% | -0.9% | — |
| May 8, 2025 | AMC | -0.47 | -0.44 | +6.4% | 3.76 | -1.6% | +0.8% | +4.0% | +3.7% | +2.7% | +5.1% | — |
| Feb 27, 2025 | AMC | -0.62 | -0.63 | -1.6% | 3.92 | -0.5% | +0.3% | -6.4% | -1.8% | +3.1% | +2.6% | — |
| Oct 31, 2024 | AMC | -0.60 | -0.56 | +6.7% | 4.76 | -0.2% | -0.2% | -1.7% | -5.0% | -0.6% | +11.3% | — |
| Aug 1, 2024 | AMC | -0.53 | -0.56 | -5.7% | 6.88 | -3.2% | +2.3% | +0.0% | +2.0% | -0.7% | +1.7% | — |
| May 8, 2024 | AMC | -0.52 | -0.55 | -5.8% | 8.50 | +0.7% | +0.5% | -7.5% | -4.5% | -3.9% | -2.6% | — |
| Feb 29, 2024 | AMC | -0.37 | -0.53 | -43.2% | 10.27 | -0.6% | +11.8% | +12.0% | +5.8% | +6.2% | +9.8% | — |
| Nov 2, 2023 | AMC | -0.50 | -0.67 | -34.0% | 5.95 | +1.0% | +7.7% | +4.0% | +1.7% | -6.4% | -9.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | Jefferies | Initiates | Buy | $18 | $9.01 | $9.18 | +1.9% | +5.7% | — | — | — | — |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.89 | $8.75 | -1.6% | -5.1% | -5.7% | +1.9% | +1.3% | — |
| Apr 24 | B. Riley Securities | Initiates | Buy | $17 | $9.15 | $9.72 | +6.2% | +4.7% | -2.8% | -7.8% | -8.4% | -1.0% |
| Apr 20 | BTIG | Maintains | Buy → Buy | — | $6.66 | $8.65 | +29.9% | +42.0% | +38.9% | +31.4% | +37.4% | +43.8% |
| Mar 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.62 | $5.50 | -2.1% | +0.4% | -4.4% | -6.8% | -1.6% | +0.0% |
| Mar 25 | Morgan Stanley | Maintains | Overweight → Overweight | — | $5.22 | $5.31 | +1.7% | +7.7% | +8.0% | +2.9% | +0.4% | +5.9% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.90 | $6.73 | -2.5% | +1.7% | +0.7% | +2.2% | -1.7% | -4.6% |
| Feb 18 | RBC Capital | Maintains | Outperform → Outperform | — | $7.63 | $8.26 | +8.3% | +10.7% | +8.3% | +5.5% | +2.9% | +4.7% |
| Feb 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.63 | $8.26 | +8.3% | +10.7% | +8.3% | +5.5% | +2.9% | +4.7% |
| Feb 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.63 | $8.26 | +8.3% | +10.7% | +8.3% | +5.5% | +2.9% | +4.7% |
Recent Filings
8-K · 7.01
! Medium
COMPASS Pathways Plc American Depository Shares -- 8-K 7.01: Regulation FD Disclosure
COMPASS Pathways priced a public offering on February 18, 2026, though specific terms remain unavailable in this filing disclosure.
Feb 19
8-K · 8.01
!! High
COMPASS Pathways Plc American Depository Shares -- 8-K 8.01: Material Event / Announcement
COMPASS Pathways achieved the primary endpoint in its Phase 3 COMP006 trial for COMP360 psilocybin treating treatment-resistant depression, meeting efficacy criteria for potential regulatory approval.
Feb 17
Data updated apr 26, 2026 10:12am
· Source: massive.com